Literature DB >> 1916055

Characterization of the insulin-antagonistic effect of growth hormone in man.

J Fowelin1, S Attvall, H von Schenck, U Smith, I Lager.   

Abstract

The insulin-antagonistic effect of growth hormone was characterized by infusing the hormone at three different infusion rates (6, 12 or 24 mU.kg-1.min-1) for one h in 11 healthy subjects. The insulin effect was measured with the euglycaemic clamp technique combined with D-(3-3H)-glucose infusion to evaluate glucose production and utilization. A control study with NaCl (154 mmol.l-1) infusion was also performed. The insulin levels during the clamps were similar in all studies (36 +/- 0.2 mU.l-1). Peak growth hormone levels were reached at 60 min (growth hormone 6 mU.kg-1.h-1: 31 +/- 5; growth hormone 12 mU.kg-1.h-1: 52 +/- 4 and growth hormone 24 mU.kg-1.h-1; 102 +/- 8 mU.l-1). The insulin-antagonistic effect of growth hormone started after approximately 2 h, was maximal after 4-5 h (approximately 39% inhibition of glucose infusion rate between control and growth hormone 24 mU.kg-1.h-1) and lasted for 6-7 h after peak levels. The resistance was due to a less pronounced insulin effect both to inhibit glucose production and to stimulate glucose utilization. Growth hormone infusion of 12 mU.kg-1.h-1 induced a similar insulin-antagonistic effect as the higher infusion rate whereas 6 mU.kg-1.h-1 induced a smaller response with a duration of 1 h between 3-4 h after peak levels of growth hormone. The present study demonstrates that growth hormone levels similar to those frequently seen in Type 1 (insulin-dependent) diabetic patients during poor metabolic control or hypoglycaemia, have pronounced insulin-antagonistic effects.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1916055     DOI: 10.1007/bf00403286

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  37 in total

1.  Combined effect of growth hormone and cortisol on late posthypoglycemic insulin resistance in humans.

Authors:  J Fowelin; S Attvall; H Von Schenck; U Smith; I Lager
Journal:  Diabetes       Date:  1989-11       Impact factor: 9.461

2.  Antilipolytic effects of growth hormone.

Authors:  H M Goodman
Journal:  Metabolism       Date:  1970-10       Impact factor: 8.694

3.  Both human pituitary growth hormone and recombinant DNA-derived human growth hormone cause insulin resistance at a postreceptor site.

Authors:  R G Rosenfeld; D M Wilson; L A Dollar; A Bennett; R L Hintz
Journal:  J Clin Endocrinol Metab       Date:  1982-05       Impact factor: 5.958

4.  Postprandial hyperglycaemia following a morning hypoglycaemia in type 1 diabetes mellitus.

Authors:  J Fowelin; S Attvall; H von Schenck; U Smith; I Lager
Journal:  Diabet Med       Date:  1990-02       Impact factor: 4.359

5.  Importance of raised growth hormone levels in mediating the metabolic derangements of diabetes.

Authors:  M Press; W V Tamborlane; R S Sherwin
Journal:  N Engl J Med       Date:  1984-03-29       Impact factor: 91.245

6.  Experimental validation of measurements of glucose turnover in nonsteady state.

Authors:  J Radziuk; K H Norwich; M Vranic
Journal:  Am J Physiol       Date:  1978-01

7.  Alterations in the pulsatile mode of growth hormone release in men and women with insulin-dependent diabetes mellitus.

Authors:  C M Asplin; A C Faria; E C Carlsen; V A Vaccaro; R E Barr; A Iranmanesh; M M Lee; J D Veldhuis; W S Evans
Journal:  J Clin Endocrinol Metab       Date:  1989-08       Impact factor: 5.958

8.  Growth hormone response to hyperinsulinaemia in insulin-dependent diabetics. Comparison of patients with and without retinopathy.

Authors:  P S Sharp; K Foley; F Vitelli; F Maneschi; E M Kohner
Journal:  Diabet Med       Date:  1984-05       Impact factor: 4.359

9.  Insulin resistance in diabetic ketoacidosis.

Authors:  E J Barrett; R A DeFronzo; S Bevilacqua; E Ferrannini
Journal:  Diabetes       Date:  1982-10       Impact factor: 9.461

10.  Human adipose tissue in culture. VII. The long-term effect on growth hormone.

Authors:  G Nyberg; U Smith
Journal:  Horm Metab Res       Date:  1977-01       Impact factor: 2.936

View more
  11 in total

Review 1.  Molecular heterogeneity of human GH: from basic research to clinical implications.

Authors:  C L Boguszewski
Journal:  J Endocrinol Invest       Date:  2003-03       Impact factor: 4.256

2.  Contrasting metabolic effects of continuous and pulsatile growth hormone administration in young adults with type 1 (insulin-dependent) diabetes mellitus.

Authors:  B R Pal; P E Phillips; D R Matthews; D B Dunger
Journal:  Diabetologia       Date:  1992-06       Impact factor: 10.122

3.  Reduced abdominal adiposity and improved glucose tolerance in growth hormone-treated girls with Turner syndrome.

Authors:  Nicole Wooten; Vladimir K Bakalov; Suvimol Hill; Carolyn A Bondy
Journal:  J Clin Endocrinol Metab       Date:  2008-03-18       Impact factor: 5.958

4.  The effects of recombinant insulin-like growth factor I administration on growth hormone levels and insulin requirements in adolescents with type 1 (insulin-dependent) diabetes mellitus.

Authors:  T D Cheetham; J Jones; A M Taylor; J Holly; D R Matthews; D B Dunger
Journal:  Diabetologia       Date:  1993-07       Impact factor: 10.122

Review 5.  Growth hormone, IGF-I and insulin and their abuse in sport.

Authors:  R I G Holt; P H Sönksen
Journal:  Br J Pharmacol       Date:  2008-03-31       Impact factor: 8.739

6.  Growth hormone in intra-uterine growth retarded newborns.

Authors:  Sajita Setia; M G Sridhar; Vishnu Bhat; Latha Chaturvedula
Journal:  Indian J Pediatr       Date:  2007-11       Impact factor: 1.967

7.  The Effect of Growth Hormone Administration on the Regulation of Mitochondrial Apoptosis in-Vivo.

Authors:  James Keane; Lotti Tajouri; Bon Gray
Journal:  Int J Mol Sci       Date:  2015-06-05       Impact factor: 5.923

8.  A randomised controlled trial of early insulin therapy in very low birth weight infants, "NIRTURE" (neonatal insulin replacement therapy in Europe).

Authors:  Kathryn Beardsall; Sophie Vanhaesebrouck; Amanda L Ogilvy-Stuart; Jag S Ahluwalia; Christine Vanhole; Christopher Palmer; Paula Midgley; Mike Thompson; Luc Cornette; Mirjam Weissenbruch; Marta Thio; Francis de Zegher; David Dunger
Journal:  BMC Pediatr       Date:  2007-08-10       Impact factor: 2.125

9.  Recombinant human growth hormone and insulin-like growth factor-1 do not affect mitochondrial derived highly reactive oxygen species production in peripheral blood mononuclear cells under conditions of substrate saturation in-vitro.

Authors:  James Keane; Lotti Tajouri; Bon Gray
Journal:  Nutr Metab (Lond)       Date:  2016-07-04       Impact factor: 4.169

Review 10.  Gut Microbiome, Intestinal Permeability, and Tissue Bacteria in Metabolic Disease: Perpetrators or Bystanders?

Authors:  Rima M Chakaroun; Lucas Massier; Peter Kovacs
Journal:  Nutrients       Date:  2020-04-14       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.